ArticleTherapeutic advances in gastroenterology2026
Comment on: Final results from the vedolizumab extended access program multinational study demonstrate long-term treatment persistence and safety.
Joaquín Borrás-Blasco et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.